scorecardresearch
Wednesday, July 30, 2025
TopicBig Pharma

Topic: Big Pharma

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

India banks on Hyderabad’s ‘Pharma City’ to break China’s stranglehold over drug supplies

India’s $42 billion drug manufacturing industry relies intensely on China, which supplies almost 70% of the active pharmaceutical ingredients that go into making medicines.

Who’s responsible if vaccines go wrong? Pharma companies or govts? There are no easy answers

Given the speed of vaccine production, there are few answers for what Pharma companies & govts are ultimately responsible for.

Covid pandemic gives businesses plenty of reasons to get back to dealmaking

It was the pharma industry that kicked off the global megamerger wave last time around, in early 2014.

Big pharma is looking beyond coronavirus with AstraZeneca eyeing merger with Gilead

The suggestion of a blockbuster merger between the two drugmakers is a sign that the industry is getting back to something resembling business as usual.

Big Pharma has failed. It’s been 35 years since a new class of antibiotics entered the market

Antibiotics are among the most important medicines known to humankind, but we are running out of it.

Lucrative drugs like Viagra, Humira to lose patents but Indian pharma unlikely to gain

Indian pharma companies, which have dominated the world’s generic medicines market, are now hampered by Trump’s policies & lack of expertise in biologics.

How Ranbaxy faked manufacturing data for all drugs not only in India, but in US, Europe too

Ranbaxy was treating data as an entirely fungible marketing tool, apparently without consideration of impact on patients. It was an outright fraud.

On Camera

No one should have to choose between a roof and two meals. But India’s migrants do, every day

India’s policymakers need to ensure that labourers, and milk and newspaper delivery workers, do not have to sacrifice food just to keep a roof over their heads.

Govt’s earlier FDI limit of 74% in insurance sector has remained underutilised, Parliament told

In the latest budget, the FDI limit was increased to 100 percent, but most foreign companies are not buying such large stakes in the Indian insurance sector.

India’s air defence system foiled 1,000 Pakistani drone attacks on 9 May—Modi tells Parliament

New Delhi: India’s air defence systems intercepted and destroyed 1,000 drones and missiles launched by Pakistan on 9 May during Op Sindoor, Prime Minister...

Modi’s Bharat vs Indira’s India: 11-yr report card of politics, diplomacy, economy, nationalism

As Narendra Modi becomes India’s second-longest consecutively serving Prime Minister, we look at how he compares with Indira Gandhi across four key dimensions.